5CV Stock Overview
A biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
CureVac N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.62 |
| 52 Week High | US$5.71 |
| 52 Week Low | US$2.11 |
| Beta | 2.61 |
| 11 Month Change | 3.48% |
| 3 Month Change | -10.27% |
| 1 Year Change | -47.18% |
| 33 Year Change | -93.55% |
| 5 Year Change | n/a |
| Change since IPO | -94.95% |
Recent News & Updates
Recent updates
Shareholder Returns
| 5CV | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 7.5% | -0.7% | 0.2% |
| 1Y | -47.2% | -17.2% | 8.5% |
Return vs Industry: 5CV underperformed the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: 5CV underperformed the German Market which returned 8.5% over the past year.
Price Volatility
| 5CV volatility | |
|---|---|
| 5CV Average Weekly Movement | 6.3% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: 5CV has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 5CV's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 1,086 | Alexander Zehnder | www.curevac.com |
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer.
CureVac N.V. Fundamentals Summary
| 5CV fundamental statistics | |
|---|---|
| Market cap | €569.47m |
| Earnings (TTM) | -€278.43m |
| Revenue (TTM) | €65.86m |
8.6x
P/S Ratio-2.0x
P/E RatioIs 5CV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5CV income statement (TTM) | |
|---|---|
| Revenue | €65.86m |
| Cost of Revenue | €152.13m |
| Gross Profit | -€86.27m |
| Other Expenses | €192.16m |
| Earnings | -€278.43m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.24 |
| Gross Margin | -131.00% |
| Net Profit Margin | -422.77% |
| Debt/Equity Ratio | 0% |
How did 5CV perform over the long term?
See historical performance and comparison